表紙
市場調查報告書

高磷血症:管道產品分析

Hyperphosphatemia - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 950842
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
高磷血症:管道產品分析 Hyperphosphatemia - Pipeline Review, H1 2020
出版日期: 2020年06月30日內容資訊: 英文 80 Pages
簡介
高磷血症,即異常高的血清磷酸鹽水平與磷酸鹽吸收增加,磷酸鹽排泄減少或將細胞內磷酸鹽轉移到細胞外空間的疾病有關。這可能是由於。這種情況在慢性腎臟疾病患者中最常見。體徵和症狀包括疲勞,噁心,睡眠障礙,呼吸急促,骨骼和關節疼痛,瘙癢和皮疹。用磷酸鹽粘合劑和利尿劑進行治療。

本報告描述了針對高磷血症的治療藥物開發管線的當前狀態,並對每個開發階段進行了最新分析,公司和研究機構正在開發的治療藥物,治療藥物的評估以及後一個術語的比較分析。我們還提供有關已上演和中止的項目的信息,以及最新的新聞和公告。

內容

目錄

表格列表

圖列表

  • 簡介
  • 調查範圍
  • 高磷酸鹽血症-概述
  • 高磷血症-治療藥物的開發
  • 管道概述
  • 公司管道
  • 大學/機構管道
  • 公司正在開發的產品
  • 大學和研究機構正在開發的產品
  • 高磷血症治療評估
  • 按目標評估
  • 通過作用機制進行評估
  • 按管理途徑進行的評估
  • 按分子類型評估
  • 高磷血症-參與治療藥物開發的公司
  • 3SBio Inc
  • Ardelyx Inc
  • China Nuokang Bio-Pharmaceutical Inc
  • Chugai Pharmaceutical Co Ltd
  • Citragen Pharmaceuticals Inc
  • J-Pharma Co Ltd
  • OPKO Health Inc
  • Panion&Bf Biotech Inc
  • Shield Therapeutics Plc
  • Unicycive Therapeutics Inc
  • Vidasym Inc
  • 高磷血症-藥物概況
  • CGN-002-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • 氯化膽甾醇-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • EOS-789-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • 鐵酸鹽-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • 檸檬酸鐵-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • JPH-101-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • 藍丹聚苯乙烯磺酸鹽-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • PT-20-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • 小分子高磷酸鹽血症-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • 鹽酸tenapanor-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • UNI-494-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • VS-501-藥物概況
  • 產品說明
  • 作用機理
  • 研發進展
  • 高磷血症休眠項目
  • 高磷血症停產的產品
  • 高磷血症-產品開發的里程碑
  • 精選新聞和新聞稿
  • 2020年6月15日:Ardelyx宣佈了一項正在進行的NORMALIZE第四階段研究的陽性第二數據分析,該研究旨在評估CKD患者透析中的替納帕諾
  • 2019年12月4日:Ardelyx報告Tenapanor III期CKD試驗的陽性數據
  • 2019年11月6日:Ardelyx在2019年腎臟周宣佈演講
  • 2019年10月15日:Akebia起訴CMS:FDA批准針對缺鐵性貧血的FDA批准的Auryxia的Medicare Part D適應症於2018年取消高磷血症適應症施加事先批准要求
  • 2019年9月3日:Ardelyx陽性關鍵的3期AMPLIFY研究評估了儘管採用磷酸鹽結合劑治療,但血漿高磷血症不受控制的透析患者中□□Tenapanor的療效公佈結果
  • 2019年3月7日:Ardelyx發表了Tenapanor在美國腎臟病學院治療高磷酸鹽血症的III期臨床陽性結果的同行評審論文
  • 2019年2月7日:Ardelyx合作夥伴Kyowa Hakko Kirin宣佈開始對日本高磷酸鹽血症患者進行透析治療Tenapanor的II期臨床試驗
  • 2018年10月26日:Ardelyx發佈了新的臨床前數據,顯示Tenapanor和Sevelamer聯合使用對血磷升高的協同作用
  • 2018年8月29日:Ardelyx宣佈發表《科學轉化醫學》(Science Translational Medicine),其中詳述了Tenapanor抑制旁細胞磷酸鹽吸收的獨特作用機制。
  • 2018年5月21日:Ardelyx與Solar Capital和Bridge Bank達成5000萬美元的貸款協議
  • 2017年11月21日:Ardelyx宣佈Tenapanor的更新開發路徑
  • 2017年4月18日:Ardelyx在即將舉行的春季醫學會議上宣佈Tenapanor
  • 2017年2月15日:Ardelyx宣佈Tenapanor治療晚期腎病患者高磷酸鹽血症的III期臨床試驗成功
  • 2017年1月6日:Shield Therapeutics提供PT20更新
  • 2016年10月14日:Keryx Biopharmaceuticals在美國腎臟病學會腎臟週2016年年會上公佈數據
  • 附錄
  • 調查方法
  • 調查範圍
  • 二次調查
  • 主要調查
  • 專家小組驗證
  • 聯繫我們
  • 免責聲明
目錄
Product Code: GMDHC12323IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides an overview of the Hyperphosphatemia (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperphosphatemia (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 2, 1, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hyperphosphatemia (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia (Nutritional Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperphosphatemia (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperphosphatemia (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia (Nutritional Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia (Nutritional Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperphosphatemia - Overview
  • Hyperphosphatemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hyperphosphatemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hyperphosphatemia - Companies Involved in Therapeutics Development
  • 3SBio Inc
  • Ardelyx Inc
  • China Nuokang Bio-Pharmaceutical Inc
  • Chugai Pharmaceutical Co Ltd
  • Citragen Pharmaceuticals Inc
  • J-Pharma Co Ltd
  • OPKO Health Inc
  • Panion & Bf Biotech Inc
  • Shield Therapeutics Plc
  • Unicycive Therapeutics Inc
  • Vidasym Inc
  • Hyperphosphatemia - Drug Profiles
  • CGN-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • colestilan chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EOS-789 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fermagate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ferric citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JPH-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lanthanum polystyrene sulfonate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PT-20 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Hyperphosphatemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tenapanor hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • UNI-494 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VS-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hyperphosphatemia - Dormant Projects
  • Hyperphosphatemia - Discontinued Products
  • Hyperphosphatemia - Product Development Milestones
  • Featured News & Press Releases
  • Jun 15, 2020: Ardelyx announces positive second data analysis from ongoing NORMALIZE phase 4 study evaluating Tenapanor in CKD patients on dialysis
  • Dec 04, 2019: Ardelyx reports positive data from tenapanor's Phase III CKD trial
  • Nov 06, 2019: Ardelyx announces presentation at Kidney Week 2019
  • Oct 15, 2019: Akebia files lawsuit against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia for its Iron Deficiency Anemia Indication and imposing a prior authorization requirement for its Hyperphosphatemia indication
  • Sep 03, 2019: Ardelyx announces positive results from the pivotal phase 3 AMPLIFY study evaluating tenapanor in dialysis patients who have uncontrolled hyperphosphatemia despite phosphate binder treatment
  • Mar 07, 2019: Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
  • Feb 07, 2019: Ardelyx collaboration partner, Kyowa Hakko Kirin, announces initiation of a phase 2 clinical study of Tenapanor for Hyperphosphatemia patients on dialysis in Japan
  • Oct 26, 2018: Ardelyx presents new preclinical data demonstrating synergy between Tenapanor and Sevelamer when dosed in combination for elevated serum phosphorus
  • Aug 29, 2018: Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
  • May 21, 2018: Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
  • Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor
  • Apr 18, 2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings
  • Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
  • Jan 06, 2017: Shield Therapeutics Provides Update on PT20
  • Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Hyperphosphatemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Hyperphosphatemia - Pipeline by 3SBio Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Ardelyx Inc, H1 2020
  • Hyperphosphatemia - Pipeline by China Nuokang Bio-Pharmaceutical Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
  • Hyperphosphatemia - Pipeline by Citragen Pharmaceuticals Inc, H1 2020
  • Hyperphosphatemia - Pipeline by J-Pharma Co Ltd, H1 2020
  • Hyperphosphatemia - Pipeline by OPKO Health Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Shield Therapeutics Plc, H1 2020
  • Hyperphosphatemia - Pipeline by Unicycive Therapeutics Inc, H1 2020
  • Hyperphosphatemia - Pipeline by Vidasym Inc, H1 2020
  • Hyperphosphatemia - Dormant Projects, H1 2020
  • Hyperphosphatemia - Discontinued Products, H1 2020

List of Figures

List of Figures

  • Number of Products under Development for Hyperphosphatemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020